on ONCODESIGN PRECISION MEDICINE S.A. (isin : FR001400CM63)
OPM presents its 2026 half-year financial results
Oncodesign Precision Medicine (OPM) has released its financial results for the first half of 2026. Funding has been secured from the Michael J. Fox Foundation for the development of OPM-201 for Parkinson's disease. In addition, the company is making progress in the clinical trial of OPM-101 for advanced melanoma.
Despite a 21% reduction in revenue, operating expenses have been significantly reduced since 2024. This has led to a 32% improvement in operating result, reaching -€2.2 million, excluding the exceptional effect of inventory in 2025.
With €2.86 million in cash reserves as of June 30, 2026, including an initial payment from the foundation, OPM is continuing its discussions to secure new partners and funding. However, its continued operation remains contingent upon obtaining additional funds.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ONCODESIGN PRECISION MEDICINE S.A. news